Rose Marie Cubbon from 21 Beacon St APT 4I, Boston, MA 02108, age 69

Us Patents

1B20 Pcsk9 Antagonists
view source
US Patent:

8188233, May 29, 2012
Filed:

Feb 6, 2009
Appl. No.:

12/322861
Inventors:

Jon H. Condra - Doylestown PA, US
Rose M. Cubbon - Fanwood NJ, US
Holly A. Hammond - Telford PA, US
Timothy McCabe - Doylestown PA, US
Shilpa Pandit - Edison NJ, US
Laurence B. Peterson - Westfield NJ, US
Joseph C. Santoro - Belle Mead NJ, US
Ayesha Sitlani - Metuchen NJ, US
Dana D. Wood - Collegeville PA, US
Henryk Mach - Ambler PA, US
Heidi Yoder - Glenside PA, US
Sonia M. Gregory - Blue Bell PA, US
Jeffrey T. Blue - Telford PA, US
Kevin Wang - Lansdale PA, US
Peter Luo - Lansdale PA, US
Denise K. Nawrocki - Annandale NJ, US
Pingyu Zhong - Blue Bell PA, US
Feng Dong - Lansdale PA, US
Yan Li - San Jose CA, US
Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:

C07K 16/00
A61K 39/395
C12N 5/07
C12N 5/16
US Classification:

5303871, 4241301, 435326
Abstract:

Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

1D05 Pcsk9 Antagonists
view source
US Patent:

8188234, May 29, 2012
Filed:

Feb 6, 2009
Appl. No.:

12/322867
Inventors:

Jon H. Condra - Doylestown PA, US
Rose M. Cubbon - Fanwood NJ, US
Holly A. Hammond - Telford PA, US
Laura Orsatti - Pomezia, IT
Shilpa Pandit - Edison NJ, US
Laurence B. Peterson - Westfield NJ, US
Joseph C. Santoro - Belle Mead NJ, US
Ayesha Sitlani - Metuchen NJ, US
Dana D. Wood - Collegeville PA, US
Henryk Mach - Ambler PA, US
Heidi Yoder - Glenside PA, US
Sonia M. Gregory - Blue Bell PA, US
Jeffrey T. Blue - Telford PA, US
Kevin Wang - Lansdale PA, US
Peter Luo - Lansdale PA, US
Denise K. Nawrocki - Annandale NJ, US
Pingyu Zhong - Blue Bell PA, US
Feng Dong - Lansdale PA, US
Yan Li - San Jose CA, US
Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:

C07K 16/00
A61K 39/395
C12N 5/07
C12N 5/16
US Classification:

5303871, 4241301, 435326
Abstract:

Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Benzimisazo[4,5-F]Isoquinolinone Derivatives
view source
US Patent:

20040176601, Sep 9, 2004
Filed:

Jan 30, 2004
Appl. No.:

10/485720
Inventors:

Joung Goulet - Wetsfield NJ, US
Rose Cubbon - Fanwood NJ, US
Richard Cummings - Fanwood NJ, US
Xingfang Hong - Westfield NJ, US
Peter Sinclair - Scotch Plains NJ, US
James Thompson - Fanwood NJ, US
International Classification:

C07D491/14
US Classification:

546/046000
Abstract:

Benzimidazo[4,5-f]isoquinolinone derivatives are inhibitors of Janus protein tyrosine kinases (Jak), and as such are useful as immunosuppressants, and in the treatment of diseases including asthma, allergies, autoimmune diseases.

Pcsk9 Immunoassay
view source
US Patent:

20110306060, Dec 15, 2011
Filed:

Dec 2, 2009
Appl. No.:

13/139045
Inventors:

Yan Ni - Westfield NJ, US
Ayesha Sitlani - Metuchen NJ, US
Shilpa Pandit - Edison NJ, US
Dale Lewis - Washington Crossing PA, US
Xun Shen - Piscataway NJ, US
Sharon Lobo - Hackettstown NJ, US
Timothy McCabe - Doylestown PA, US
Jon Condra - Doylestown PA, US
Rose Cubbon - Fanwood NJ, US
International Classification:

G01N 33/573
US Classification:

435 74
Abstract:

Methods of using PCSK antagonists More specifically, methods for measuring circulating PCSK levels in a bio-logical sample by means of an immunoassay The immunoassay used can be a solid phase immunoassay, such as a dissociation-enhanced lanthanide fluorescence immunoassay utilizing an E capture antibody or coating and a G or H detecting antibody.

Ax213 And Ax132 Psck9 Antagonists And Variants
view source
US Patent:

20120213794, Aug 23, 2012
Filed:

Oct 29, 2010
Appl. No.:

13/503729
Inventors:

Peter Peizhi Luo - Lansdale PA, US
Pingyu Zhong - Blue Bell PA, US
Mark Hsieh - Jenkintown PA, US
Yan Li - San Jose CA, US
Xinwei Wang - Germantown MD, US
Feng Dong - Lansdale PA, US
Andrei Golosov - Cambridge MA, US
Yan Ni - Westfield NJ, US
Weirong Wang - Harleysville PA, US
Laurence B. Peterson - Westfield NJ, US
Rose Cubbon - Fanwood NJ, US
Sujata Sharma - Eagleville PA, US
Jon Condra - Doylestown PA, US
Jun Lu - Lansdale PA, US
Gopalakrishnan Parthasarathy - Hillsborough NJ, US
Stephen Soisson - Hillsborough NJ, US
Noel Byrne - Doylestown PA, US
International Classification:

A61K 39/395
C12N 15/13
C12P 21/02
A61P 3/06
C12N 5/10
C12N 1/19
C12N 1/21
C07K 16/40
C12N 15/63
US Classification:

4241461, 53038826, 536 2353, 435 696, 4353201, 435338, 43525423, 435419, 43525233, 43525231, 43525235
Abstract:

Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Antagonists Of Pcsk9
view source
US Patent:

20120219558, Aug 30, 2012
Filed:

Sep 15, 2010
Appl. No.:

13/497663
Inventors:

Yan Ni - Westfield NJ, US
Ayesha Sitlani - Metuchen NJ, US
Shilpa Pandit - Edison NJ, US
Dale Lewis - Washington Crossing PA, US
Xun Shen - Piscataway NJ, US
Sharon Lobo - Hackettstown NJ, US
Timothy McCabe - Doylestown PA, US
Jon Condra - Doylestown PA, US
Rose Cubbon - Fanwood NJ, US
Fubao Wang - Drescher PA, US
International Classification:

A61K 39/395
C12N 15/13
C12N 1/21
C12N 15/63
C12P 21/08
C07K 16/40
A61P 7/00
US Classification:

4241461, 53038826, 536 2353, 4353201, 435 696, 43525233
Abstract:

Antagonists of human proprotein convertase subtilisin-kexin type 9 (PCSK9) are disclosed. Said antagonists are effective in the inhibition of PCSK9 function and thereby provide compositions of matter useful for the treatment of conditions associated with PCSK9 activity. The present invention further discloses nucleic acids encoding PCSK9 antagonists as well as methods of making and using PCSK9 antagonists.

Ax1 And Ax189 Psck9 Antagonists And Variants
view source
US Patent:

20120231005, Sep 13, 2012
Filed:

Oct 29, 2010
Appl. No.:

13/503726
Inventors:

Peter Peizhi Luo - Lansdale PA, US
Kevin Caili Wang - Lansdale PA, US
Pingyu Zhong - Blue Bell PA, US
Mark Hsieh - Jenskintown PA, US
Yan Li - San Jose CA, US
Xinwei Wang - Germantown MD, US
Feng Dong - Lansdale PA, US
Andrei Golosov - Cambridge MA, US
Yan Ni - Westfield NJ, US
Weirong Wang - Harleysville PA, US
Laurence B. Peterson - Westfield NJ, US
Rose Cubbon - Fanwood NJ, US
International Classification:

C07K 16/40
C12N 9/99
C12N 1/21
C12N 15/13
C12N 5/10
C12P 21/02
A61K 39/395
C12N 15/63
C12N 1/19
US Classification:

4241391, 4353201, 435184, 43525233, 43525231, 43525235, 4352542, 435338, 435419, 435 692, 5303898, 4241581, 536 2353, 5303879, 435331
Abstract:

Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

1D05 Pcsk9 Antagonists
view source
US Patent:

20120301461, Nov 29, 2012
Filed:

May 8, 2012
Appl. No.:

13/466439
Inventors:

Jon H. Condra - Doylestown PA, US
Rose M. Cubbon - Fanwood NJ, US
Holly A. Hammond - Telford PA, US
Laura Orsatti - Ponezia, IT
Shilpa Pandit - Edison NJ, US
Laurence B. Peterson - Westfield NJ, US
Joseph C. Santoro - Belle Mead NJ, US
Ayesha Sitlani - Metuchen MA, US
Dana D. Wood - Collegeville PA, US
Henryk Mach - Amber PA, US
Heidi Yoder - Glenside PA, US
Sonia M. Gregory - Charlottesville VA, US
Jeffrey T. Blue - Telford PA, US
Kevin Wang - Lansdale PA, US
Peizhi (Peter) Luo - Lansdale PA, US
Denise K. Nawrocki - Annandale NJ, US
Pingyu Zhong - Blue Bell PA, US
Feng Dong - Lansdale PA, US
Yan Li - San Jose CA, US
International Classification:

C07K 16/40
C12N 15/13
C12N 1/21
A61P 9/00
C12N 7/01
C12N 5/10
C12P 21/00
A61K 39/395
C12N 1/19
US Classification:

4241331, 5303873, 5303891, 536 2353, 4353201, 43525233, 43525231, 43525235, 4352542, 4352351, 435325, 435 696
Abstract:

Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.